EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD : A UK Biobank Study

Josh Bilson iD, Theresa J Hydes iD, Declan McDonnell iD, Ryan M Buchanan iD, Eleonora Scorletti iD, Alessandro Mantovani iD, Giovanni Targher iD, Christopher D Byrne iD

Liver International · 2025-04 · 45 (4)

DOI: 10.1111/liv.16159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 15.11.2024. Verfasst von Josh Bilson und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Metabolic Syndrome, Renal Insufficiency, Chronic, Kidney Failure, Chronic, Fatty Liver. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parnell Diabetes Trust, University Hospital Southampton Charity, Università degli Studi di Verona.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The impact of metabolic syndrome (MetS) traits on chronic kidney disease (CKD) risk in metabolic dysfunction‐associated steatotic liver disease (MASLD) is unknown. We investigated the impact of type and number of MetS traits and liver fibrosis on prevalent CKD and incident end‐stage renal disease (ESRD) risk in SLD.

Methods

234 488 UK Biobank participants' were analysed. Hepatic steatosis index (> 36 for SLD, < 30 for no SLD) and MRI‐proton density fat fraction (≥ 5.56%) were used to identify SLD. MetS traits were identified using MASLD criteria. Advanced fibrosis (FIB‐4 score > 2.67) was determined using FIB‐4 scores. eGFR < 60 mL/min/1.73 m 2 or albuminuria > 3 mg/mmol identified prevalent CKD. A validated algorithm identified incident ESRD. Binary logistic and Cox regressions were used to test associations with prevalent CKD ([adjusted odds ratios (ORs)]) and incident ESRD (adjusted hazard ratios [HRs]) respectively.

Results

102 410 participants (41.2%) had SLD. 64.4% had MetS. 1.3% had FIB‐4 score > 2.67. With SLD and only one MetS trait, hypertension (OR 1.35, 95% CI 1.35–1.72) or type 2 diabetes (T2D) (OR 1.89, 95% CI 1.06–3.38) increased risk of prevalent CKD. MetS (≥ 3 traits) increased prevalent CKD risk (OR 1.94, 95% CI 1.75–2.15), which was further increased by advanced liver fibrosis (OR 4.29, 95% CI 3.36–5.47). CKD prevalence increased with increasing MetS traits. Over 13.6 years (median follow‐up), MetS was associated with increased risk of developing ESRD (HR 1.70, 95% CI 1.19–2.43).

Conclusions

In MASLD, hypertension, and T2D, number of MetS traits and liver fibrosis increased risk of prevalent CKD and presence of MetS increased the risk of incident ESRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeRenal Insufficiency, ChronicKidney Failure, ChronicFatty LiverLiver CirrhosisHumansMaleFemaleMiddle AgedUnited KingdomAgedRisk FactorsPrevalenceIncidenceBiological Specimen BanksProportional Hazards ModelsAdultLogistic ModelsUK Biobank

Stichwörter der Autor:innen

end‐stage renal diseasehypertensionmetabolic dysfunction‐associated steatotic liver diseasetype 2 diabetes

Autor:innen und Institutionen

  • School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
  • National Institute for Health and Care Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service Foundation Trust, Southampton, UK.
  • Department of Cardiovascular and Metabolic Medicine, 3rd Floor Clinical Sciences Centre, Institute of Life Course and Medical Sciences, Liverpool University Hospitals NHS Foundation Trust, University of Liverpool, Longm…
  • University Hospital Aintree, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK.
  • HPB Unit, University Hospital Southampton, Southampton, UK.
  • Primary Care and Population Sciences Faculty of Medicine, University of Southampton, Southampton, UK.

ORCID-Profile: Josh Bilson, Theresa J Hydes, Declan McDonnell, Ryan M Buchanan, Eleonora Scorletti, Alessandro Mantovani, Giovanni Targher, Christopher D Byrne

Förderung

  • Parnell Diabetes Trust
  • University Hospital Southampton Charity
  • Università degli Studi di Verona
  • National Institute for Health Research Southampton Biomedical Research Centre

Zitieren

APA

Bilson, J., Hydes, T. J., McDonnell, D., Buchanan, R. M., Scorletti, E., Mantovani, A., Targher, G., & Byrne, C. D. (2025). Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD : A UK Biobank Study. Liver International, 45(4). https://doi.org/10.1111/liv.16159

Vancouver

Bilson J, Hydes TJ, McDonnell D, Buchanan RM, Scorletti E, Mantovani A, et al. Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD : A UK Biobank Study. Liver International. 2025;45(4). doi:10.1111/liv.16159

BibTeX
@article{Bilson2025,
  author = {Bilson, Josh and Hydes, Theresa J and McDonnell, Declan and Buchanan, Ryan M and Scorletti, Eleonora and Mantovani, Alessandro and Targher, Giovanni and Byrne, Christopher D},
  title = {Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD : A UK Biobank Study},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {4},
  doi = {10.1111/liv.16159}
}
Kostenlos starten →